WFA
ITOS

Wipfli Financial Advisors’s iTeos Therapeutics ITOS Stock Holding History

Wipfli Financial Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$7K Buy
+372
New +$8.57K ﹤0.01% 1967

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Wipfli Financial Advisors's ITOS Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in iTeos Therapeutics (ITOS) in Q3 2022: 372 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #1967 among its holdings.

143 funds tracked by Wall St. Rank hold ITOS as of Q3 2022.

  • Wipfli Financial Advisors held 372 shares of iTeos Therapeutics worth $7K as of Q3 2022.
  • iTeos Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
  • iTeos Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1967 holding.
  • 143 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.